甲状腺眼病(Graves眼病):临床表现、流行病学、发病机制与管理
本文综述甲状腺眼病的临床表现、流行病学、发病机制和管理。多数患者为轻度(77%),中重度占22%,危及视力者仅1%。吸烟、男性、高龄、糖尿病、高胆固醇血症、放射性碘治疗及TSHR抗体等为危险因素。替普罗妥单抗可显著改善中重度患者预后,但副作用、费用及复发率限制其使用,静脉糖皮质激素仍是许多地区的首选治疗。
要点
- 甲状腺眼病以眼外肌肿胀和眶脂肪增多为特征,表现为眼睑退缩、水肿、眼球突出、复视和视神经病变。
- 大多数患者(77%)为轻度,22%为中重度,仅1%危及视力;高达5%的患者甲状腺功能正常或减退。
- TSHR抗体在超过95%的患者中可检测到,且与疾病活动度和严重度直接相关;TSHR是主要自身抗原。
核心结论
- 甲状腺眼病多数为轻度,但部分患者可进展为中重度或危及视力;TSHR是主要自身抗原,TSHR与IGF-1R通过β-抑制蛋白支架发生交叉对话。
- 替普罗妥单抗可显著改善中重度甲状腺眼病预后,包括较静脉甲泼尼龙更显著的眼球突出减少,但其副作用(如30%患者听力损失)、高费用和高复发率限制其使用;静脉糖皮质激素仍是许多地区的首选治疗。
- 托珠单抗是激素抵抗患者的有效治疗选择;本综述还讨论了替代药物、手术治疗、局部措施以及生活质量评估和多学科协作的重要性。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 甲状腺眼病以眼外肌肿胀和眶脂肪增多为特征,机制涉及眼睑退缩、眼睑和结膜水肿充血、眼球突出、复视和视神经病变。
- 疾病严重程度:轻度占77%,中重度占22%,危及视力者仅占1%。
- 多数甲状腺眼病患者有Graves甲状腺功能亢进症,但高达5%的患者甲状腺功能正常甚至减退。
- 危险因素包括男性、高龄、吸烟、糖尿病、高胆固醇血症、甲状腺功能亢进病程、放射性碘治疗以及促甲状腺激素受体(TSHR)抗体存在(超过95%患者可检测到,且与疾病活动度和严重度直接相关)。
- 用TSHR(而非胰岛素样生长因子-1受体(IGF-1R))对小鼠进行基因免疫可提供可靠的甲状腺眼病动物模型,表明TSHR是该病的主要自身抗原;TSHR与IGF-1R通过β-抑制蛋白支架发生交叉对话。
关键数值与推荐
- 替普罗妥单抗是一种不与TSHR结合的人源单克隆抗体,可阻断IGF-1R,已显示能显著改善中重度甲状腺眼病的预后,包括较静脉甲泼尼龙更显著的眼球突出减少。
- 替普罗妥单抗的缺点包括副作用(如30%患者听力损失)、高费用和高复发率。
- 托珠单抗阻断白细胞介素-6受体,是激素抵抗的甲状腺眼病患者的有效治疗选择。
临床怎么用
- 静脉糖皮质激素仍是世界上许多地区的首选治疗。
- 托珠单抗是激素抵抗的甲状腺眼病患者的有效治疗选择。
- 本综述讨论了替代药物、手术治疗、局部措施以及生活质量评估和多学科协作的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thyroid eye disease (TED; also known as Graves' orbitopathy), causes swollen extraocular muscles and orbital fat. Mechanistically, TED involves lid retraction, oedema and redness of the eyelids and conjunctiva, proptosis, diplopia, and optic neuropathy. Investigation of TED involves assessment of disease activity (inflammation) and disease severity. TED is predominantly mild in 77% of cases, moderate-to-severe in 22%, and rarely sight-threatening in 1% of patients. While most patients with TED have Graves' hyperthyroidism, up to 5% are euthyroid or even hypothyroid. Risk factors include male sex, older age, smoking, diabetes, hypercholesterolaemia, duration of hyperthyroidism, radioactive iodine therapy, and the presence of thyrotropin receptor (TSHR) antibodies (detectable in more than 95% of patients and directly related to TED activity and severity). Genetic immunisation of mice with TSHR, but not with insulin-like growth factor-1 receptor (IGF-1R), provides a reliable animal model of TED, demonstrating that TSHR is the primary autoantigen in the disease. Crosstalk between TSHR and IGF-1R occurs via a β-arrestin scaffold. Teprotumumab, a human monoclonal antibody that blocks IGF-1R without binding to TSHR, has been shown to significantly improve outcomes in moderate-to-severe TED, including greater proptosis reduction compared with intravenous methylprednisolone. However, its disadvantages include side effects (eg, hearing loss in 30% of patients), a high cost, and a high relapse rate. Therefore, intravenous steroids remain the treatment of choice in many parts of the world. Tocilizumab, which blocks the interleukin-6 receptor, is an effective treatment option for patients with TED who are steroid-resistant. This Review further discusses alternative medications, surgical treatments, local measures, and the importance of quality-of-life assessments and multidisciplinary care.
引用
- Wiersinga WM, Eckstein AK, Žarković M, et al. Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2025. PMID: 40324443. doi:10.1016/S2213-8587(25)00066-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。